Teleflex's tariff refund lifted profit. What lasts beyond it?

Teleflex's higher profit forecast rests partly on money coming back from tariffs and on a smaller share count. The medical-device maker has kept its comparable sales-growth target unchanged.

That leaves two different questions for investors: how much of this quarter's improvement came from the refund, and what can keep earnings growing after that benefit has been recognized?

A refund inside adjusted profit

Q3 adjusted earnings per share from continuing operations rose to $2.63 from $1.89. Adjusted operating margin reached 25%, up from 22% a year earlier.

Teleflex received $39.2 million of tariff refunds, including amounts tied to businesses classified as discontinued. Within continuing operations, $16.5 million related to tariffs charged this year remained in adjusted profit. A separate $8.8 million refund of prior-year tariffs was excluded from that adjusted comparison.

The company said the current-year refund added 2.9 percentage points to gross margin. That is close to the entire three-percentage-point increase in adjusted operating margin, though sales, spending and product mix also affected the result.

The forecast has changed its assumptions

Management now expects full-year adjusted EPS of $7.50 to $7.75, up from $6.90 to $7.20 in August. Research by Ticker Byline shows that the midpoint has increased about 8%, while the comparable sales-growth forecast remains at 3.5% to 4.5%.

The August earnings forecast excluded potential tariff refunds and the $250 million accelerated share buyback announced at the time. The latest forecast includes the $16.5 million refund benefit and $600 million of completed share repurchases through November 5.

Fewer shares spread earnings across a smaller base. Debt repayment is helping too: quarterly interest expense fell to $21.2 million from $31.8 million. Those benefits can continue beyond the quarter in which a refund is booked.

What the remaining business has to deliver

Comparable Q3 sales grew 3%. That measure adjusts for the acquired Vascular Intervention business, discontinued products, an Italian reimbursement adjustment and currency movements. Vascular and Surgical each grew at a mid-single-digit rate, while Interventional managed only slight growth.

The operating recovery still has distance to cover. Adjusted operating margin for the first nine months was 20.9%, below the prior year's 23.2%, despite the stronger latest quarter.

The August sale of the OEM business has already helped fund debt reduction and buybacks. The separate Acute Care and Interventional Urology sale remains pending, with management targeting year-end while allowing for a regulatory process that could extend into 2027.

Teleflex expects to use cash and revolving borrowings to pay taxes on the completed OEM sale in Q4. It is also working through integration and restructuring programs. The next earnings test is how much profit the smaller business can generate from sales and lower costs, alongside the continuing benefit of fewer shares and less interest.

Our Teleflex company profile tracks the revised forecasts, completed and pending disposals, cash generation and debt.